News RenovoRx, Inc.

Equities

RNXT

US75989R1077

Market Closed - Nasdaq Other stock markets 02:00:01 11/05/2024 am IST			5-day change	1st Jan Change
1.45 ^USD	+7.81%		+18.85%	-36.68%

16/04	RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting	CI
15/04	RenovoRx, Inc. announced that it has received $11.136652 million in funding	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024	02/05	BU
RenovoRx Regains Compliance with Nasdaq Stockholders Equity Requirement	19/04	AQ
RenovoRx Regains Compliance with Nasdaq Stockholders’ Equity Requirement	18/04	BU
Autonomix Medical Inc Covered in Benzinga Article Highlighting Innovative Nerve Treatment Tech	16/04	AQ
RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting	16/04	BU
RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting	16/04	CI
RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026	15/04	BU
RenovoRx, Inc. announced that it has received $11.136652 million in funding	15/04	CI
RenovoRx Announces $11.1 Million at Market Private Placement	08/04	BU
RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024	08/04	AQ
RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024	05/04	BU
RenovoRx, Inc. announced that it expects to receive $11.136652 million in funding	04/04	CI
RenovoRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02/04	CI
RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024	12/03	BU
RenovoRx Highlights Key Leadership Promotions	11/03	AQ
RenovoRx Highlights Key Leadership Promotions	09/03	BU
RenovoRx, Inc. Announces Executive Changes, Effective March 1, 2024	24/02	CI
RenovoRx, Inc. Appoints Ronald B. Kocak as Principal Accounting and Financial Officer	10/02	CI
RenovoRx, Inc. Announces Resignation of James Ahlers as Chief Financial Officer	10/02	CI
RenovoRx CEO Issues Letter to Shareholders	06/02	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News RenovoRx, Inc.

Equities

RNXT

US75989R1077

Summary

Filters